MoonLake Immunotherapeutics MLTX Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

MSCIMSCI

$51.4M+78.5%

General DynamicsGD

$58M-15.9%

Carrier GlobalCARR

$76M-11.6%

Keysight TechnologiesKEYS

$6M—

L3Harris TechnologiesLHX

$43M—

Duke EnergyDUK

$1B0.0%

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's debt instrument, unamortized discount (premium) and debt issuance costs, net?: MoonLake Immunotherapeutics (MLTX) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $5.94M in Q1 2026.